Early chronic obstructive pulmonary disease
Conditions
Interventions
Observation group 1 (Male participants aged = 50 years):N/A
Observation group 3(Female participants aged >= 50 years):N/A
Sponsors
China-Japan Friendship Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1.Age 18-60 years; 2.Both genders (male or female); 3.Post-bronchodilator lung function FEV1/FVC = 0.70 but FEV1 and/or FVC < 80% of predicted value, or FEV1/FVC = lower limit of normal (LLN) but FEV1 < LLN; 4.Exposure to modifiable risk factors (such as direct smoking, secondhand smoke, biomass fuel, occupational dust or chemical substances, outdoor air pollution, etc.) and/or potential treatable traits (such as chronic cough, chronic cough with phlegm, chest tightness, significant shortness of breath or difficulty with breathing after activities, frequently suffered from respiratory infection, comorbid with bronchial asthma, etc.); 5.Sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Self-reported a history of interstitial lung disease, bronchiectasis, tuberculosis-related lung damage, lung cancer, pleural effusion, or other diseases that caused restrictive ventilatory function, or underwent a lung resection surgery or lung transplantation; 2.Suffering from other major physical and/or psychological illnesses, unable to undergo questionnaire survey and physical examination; 3.Having active pulmonary tuberculosis or other infectious diseases; 4.Had a lower respiratory tract infection in the past four weeks; 5.Ever used or currently using short-acting and/or long-acting bronchodilators to treat chronic airway diseases (including but not limited to COPD, bronchial asthma, chronic bronchitis, bronchiectasis, etc.); 6.Pregnant women, or women within the first year after giving birth; 7.Currently participating in medical research involving drug and/or non-drug interventions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change of post-bronchodilator FEV1, the change of CAT score, and/or the number of acute exacerbation events of respiratory symptoms at one-year assessment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Post-bronchodilator FEV1/FVC < LLN (i.e. airflow limitation) at one-year assessment;Post-bronchodilator FEV1/FVC < 0.70 (i.e. airflow limitation) at one-year assessment;The number of acute exacerbation events of respiratory symptoms at one-year assessment;The change of post-bronchodilator FEV1 at one-year assessment;The average rate of decline with post-bronchodilator FEV1 at one-year assessment;The change of CAT score at one-year assessment; | — |
Countries
China
Contacts
Public ContactLei Jieping
China-Japan Friendship Hospital
Outcome results
None listed